Thursday was a positive day for the broad U.S. markets. All three major indices recovered handily from Wednesday’s drop. Crude oil made a solid gain in the session. The S&P 500 sectors…
Merrill Lynch recently highlighted sectors it considers a good opportunity now that are likely to outperform in the near term, and the sector that rated highest was biotechnology.
Teva and Regeneron both saw handy gains on Thursday after the companies posted positive topline results from their late-stage trial of fasinumab in patients with chronic pain from osteoarthritis (OA) of the…
Regeneron Pharmaceuticals is facing some difficulty after it received an update from the FDA on Eylea (aflibercept) Injection in patients with wet age-related macular degeneration.
Chris Lange It’s no surprise that it was only a matter of time before the usage and storage of big data and analytics would come to the health care sector, and many of the…
Friday was a relatively positive day for the broad U.S. markets. Although crude oil backed off, it is still holding just above the $70 price level. The S&P 500 sectors were split…
Regeneron Pharmaceuticals and Sanofi are committing to lowering the price of the anti-cholesterol drug Praluent.
Rheumatoid arthritis is an autoimmune disease that attacks tissues within the joints, and it is a major target of U.S. and foreign biotechnology and pharmaceutical companies.
The top analyst upgrades, downgrades and other research calls from Monday include Alcoa, CEMEX, Comerica, Facebook, General Motors, Incyte, Proofpoint and Regeneron Pharmaceuticals.
While chasing what portfolio managers own isn’t always the best idea, many people have made a lot of money by simply mimicking what legendary investors like Warren Buffett hold.
The top analyst upgrades, downgrades and other research calls from Wednesday include Capital One, Domino's, Home Depot, Mosaic, Regenron, Six Flags, U.S. Steel and Walmart.
The include American Express, Cellectis, ForeScout Technologies, Mastercard, Mueller Water, PG&E, Party City, Regeneron Pharmaceuticals and Visa.
One industry that could be a huge winner from tax reform, and may surprise some investors, is biotechnology, especially for the large cap leaders in the group.
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
The top analyst upgrades, downgrades and other research calls from Friday include Baidu, Barclays, Celgene, HPE, Intel, Kimberly-Clark, Lululemon, PayPal and Stratasys.
